Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States:

Breast Cancer including Triple Negative Breast Cancer

Intended Audience: Oncologists, Pathologists, Surgeons, Gynecologists, Radiologists, Community HCPs, Patients/Caregivers

Areas of interest based on referenced literature:

• Treatment and management of Breast Cancer and TNBC
• Education on biomarker driven testing strategies/appropriate testing modalities
• Role of NTRK gene fusion and impact of TRK gene fusion/TRK testing in treatment algorithms for Breast Cancer and TNBC
• Understanding of efficacy and safety profiles of approved TRK inhibitors in Breast Cancer and TNBC
• Multi-disciplinary approach to precision medicine
• Understanding and management of adverse event profiles

Proposal Requirements

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning objectives
• Proposed faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan (required on a quarterly basis)
• Detailed budget

Provider Justification:

• Copy of most recent accreditation letter and status
• Sample of other program(s) in similar therapeutic area

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

• Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (link)
• Hong, D et al. Long-term efficacy and safety of Larotrectinib in an integrated database of patients with TRK fusion cancer. ASCO 2021 presentation.
• Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstract 6602) (link)
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer
• Abstract PS11-06: Efficacy and safety of Larotrectinib in patients with TRK fusion breast cancer DOI: 10.1158/1538-7445.SABCS20-PS11-06. https://cancerres.aacrjournals.org/content/81/4_Supplement/PS11-06
• Maund SL, Sokol ES, Ang Houle A, Ross JS, Wilson TR. NTRK gene fusions are detected in both secretory and non-secretory breast cancers. Pathol Int. 2022 Jan 31. doi: 10.1111/pin.13204. Epub ahead of print. PMID: 35102630. https://pubmed.ncbi.nlm.nih.gov/35102630/
• Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, Thomas M, de Braud F. Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumors from a large real-world population. NPJ Precis Oncol. 2021 Sep 17;5(1):86. doi: 10.1038/s41698-021-00222-y. https://pubmed.ncbi.nlm.nih.gov/34535754/